"Given that the share price could reach $18 within
Post# of 148170
___________________________
$18?! On what revenues? Even if the BLA for combo is filed in May it could be approved if at all around Nov-Dec of this year. No time left for marketing it let alone selling in any meaningful quantities. The only other theoretical possibility is getting the CV indication approved sometime by the end of the summer, submitting the BLA (late fall) and getting it approved by the FDA in early 2021. So where is our beef in 2020--Q 1-2 2021?
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.